phase of AMI was less clear, although there was evidence of protection from ischemic damage, possibly mediated by an increase in collateral coronary blood flow.
Clinical Data
The striking beneficial results of prolonged ACE inhibitor therapy in the CONSENSUS-I trial on mortality of patients with advanced CHF have been followed by a series of trials in patients with less severe heart failure or asymptomatic LV dysfunction of any origin or limited to AMI. Consistent with the experimental data, the latter studies showed that ACE inhibition clearly produces favorable effects on mortality and LV function in selected high-risk post-AMI populations. More recent trials have addressed the role of ACE inhibition in relatively unselected patients or in those with anterior AMI in whom treatment was initiated during the first day of AMI. Overall, these trials indicate a small but definite benefit of about 5 lives saved for every 1000 patients treated (Table 1⇓) . 4.6 lives saved per 1000 treated patients. ACE inhibitors reduced mortality in all trials, except for CONSENSUS II, in which 1-month mortality (reported in the table) was not significantly higher in enalapril-allocated patients. The plan for this trial was to recruit 9000 patients, but the study was stopped after randomization of 6090 patients. In this trial, the ACE inhibitor was administered in the first 24 hours after AMI by intravenous (IV) infusion (enalaprilat) and then orally for 6 months.
Modified from Reference 21 with permission. Table 2⇓⇓ summarizes the evidence available from the literature (the results of the TRACE and SMILE studies were not available at the time of the meeting but are included for completeness, and their findings confirm previous evidence). Table 2⇓ and Fig 1⇓ summarize the background information: a decrease in the relative size of the beneficial effects is associated with a broadening of the population who might derive a clinically relevant benefit. Although the results of these trials are complementary in many ways, they also are a potential source of contradictory interpretation. For example, are the populations randomized in CONSENSUS II, GISSI-3, and ISIS-4 concordant or discordant with respect to those of the other trials? Although ongoing trials are addressing the issue of long-term secondary prevention with ACE inhibitors in patients at high risk of vascular events, no other placebo-controlled trials in the acute phase of AMI are planned. Thus, there is a need to translate the available evidence into reasonable and coherent recommendations for the use of ACE inhibitors in AMI and post-AMI patients. Collapse inline View popup CATS indicates Captopril and Thrombolysis Study; NYHA, New York Heart Association class; HF, heart failure; WMI, wall motion index; EF, ejection fraction; CAD, coronary artery disease; APE, acute pulmonary edema; Cr, serum creatinine; HBP, high blood pressure; RF, renal failure; and SBP, systolic blood pressure. To address these issues, a meeting of investigators actively involved in the principal published ACE inhibitor trials was convened to reach a consensus on ACE inhibitor use in patients with AMI.
Methods and Participants
The GISSI group invited the coordinating groups and/or principal investigators of the CONSENSUS, AIRE, SAVE, SOLVD, ISIS-4, GISSI-3, and V-HeFT trials. A few other experts were invited, to provide a wide range of opinions, and representatives of collaborative research groups from Latin America participated, to allow discussion of the problems of transferability and relevance in different health care settings.
The meeting was held in Berlin during the XII World Congress of Cardiology and the XVI Congress of the European Society of Cardiology, September 10, 1994. The members of the panel are listed in the "Appendix."
A summary of the existing data from the randomized clinical trials of ACE inhibitors in AMI was sent to all participants 1 month before the meeting to allow proper consideration and to avoid repetitive presentations. Confidential unpublished data from the GISSI-3, ISIS-4, and CCS-1 trials were also included.
The following questions were submitted to the panel at the same time to facilitate a productive and practice-oriented debate.
1. Is the primary indication for ACE inhibitor the treatment of the patients with AMI syndrome or with LV dysfunction that at any time complicates AMI? In the first case, should all patients or only those at higher risk be treated (ie, anterior AMI, large AMI)?
2. When should ACE inhibitor treatment be started? Is primary indication for ACE inhibitor the treatment of the patients with AMI syndrome or with LV dysfunction that at any time complicates AMI? In the first case, should all patients or only those at higher risk be treated (ie, anterior AMI, large AMI)?
When should ACE inhibitor treatment be started?
The two questions are presented together because the answer to question 1 is integrally related to question 2. The evidence available from the trials on ACE inhibitors is documented in detail in Tables 1⇑ and 2⇑ and may be summarized as follows. Treatment with ACE inhibitors has a beneficial effect in patients selected for the presence of LV dysfunction after AMI and in relatively unselected patients presenting with AMI. The benefit increases in patients with clinical or laboratory evidence of LV dysfunction. There is still uncertainty about treating all AMI patients without contraindications to ACE inhibitors or targeting a selected higher-risk group.
The extension of the indication of early treatment to an unselected AMI population is supported by the consideration of the following. In the absence of absolute predictive criteria, short-term treatment is likely to offer protection from LV dysfunction to many patients before they develop it. There is evidence in the GISSI-3 and ISIS-4 trials of a very early benefit (Fig 2⇓) when reliable, objective measurement of LV dysfunction may be impractical. A beneficial effect of ACE inhibitor treatment in GISSI-3 and ISIS-4 is observed across a wide range of patients, although as expected the benefit was less in patients at lower risk. For example, the GISSI-3 results show that 33 patients with an impaired hemodynamic state at entry (Killip class >1) had to be treated for 1 life to be saved; 333 patients without complications (Killip class 1) had to be treated for 1 life to be saved. Nevertheless, the number of lives saved in the group of lower-risk patients is important in absolute terms because of the greater prevalence of this group of patients (ie, 24 lives saved in Killip class 1 versus 39 in Killip class >1 in GISSI-3). The potential risk of an ACE inhibitor therapy started early after AMI is small and does not obscure its net benefit, as shown by GISSI-3 results: persistent hypotension and renal dysfunction were significantly more common among lisinopril-treated patients than among control subjects (Fig 3⇓) , and most of the cases of persistent hypotension (>80%) and more than half of those of renal dysfunction occurred within 7 days of randomization. However, a subsidiary analysis of GISSI-3 and ISIS-4 showed that in the same period (days 0 through 7) mortality was lower in the ACE inhibitor-allocated patients (Fig 2⇓) . Bar graphs showing that in GISSI-3 persistent hypotension (A) occurred chiefly during the acute phase of AMI, with >80% of the cases occurring within day 2 from randomization, while excessive renal dysfunction (B; clinically defined by attending cardiologists) occurred throughout the hospitalization. These two events were consistently more frequent in patients treated with lisinopril (patterned bar) than in control subjects (open bar). Absolute increase of events and percent contribution to total increase are shown for each time interval. Data on timing of the event are missing for 12 patients with persistent hypotension and 1 with renal dysfunction.
In conclusion, evidence of an early benefit in unselected AMI patients was considered complementary to the favorable effects in patients with LV dysfunction by some members of the panel but disputed by others. All agreed that patients with a clinically large AMI and/or current or previous LV failure should certainly be considered for early treatment with an ACE inhibitor in the absence of contraindications (eg, hypotension).
Question 3
What are the criteria for initial exclusion and subsequent withdrawal or continuation of ACE inhibitor treatment of AMI patients?
Exclusion Criteria
The safety profile of patients treated within 24 hours from the onset of symptoms appears acceptable if the following exclusion criteria are applied: high risk of further serious hemodynamic deterioration (systolic blood pressure ≤100 mm Hg) and specific contraindications (history of clinically relevant renal failure, history of bilateral stenosis of the renal arteries, or documented allergy to ACE inhibitors).

Patients with low systolic blood pressure (100 to 110 mm Hg) in the first 24 hours after the onset of symptoms should be monitored carefully.
No specific additional risk was shown in GISSI-3 or ISIS-4 for elderly patients or women, so ACE inhibitors are not contraindicated in these populations.
Withdrawal or Continuation
The consistency of data on the role of ACE inhibitors from trials in patients with LV dysfunction or heart failure complicating AMI (as in the AIRE, SAVE, and TRACE studies) strongly indicates that ACE inhibitors should be given to these patients. For this reason, if at any time after AMI clinical signs and/or symptoms of LV dysfunction occur or are diagnosed instrumentally, treatment should be continued over a long period of time. In other words, as soon as a patient becomes an "AIRE-or SAVE-like patient," he or she should be treated according to the indications of these studies (this recommendation was applied in the GISSI-3 and ISIS-4 trials).
On the other hand, if a patient does not show signs or symptoms of LV dysfunction, it is likely that treatment can be stopped safely after 4 to 6 weeks (based on existing evidence from GISSI-3 and ISIS-4). In this case, the patients should ideally be reevaluated after a reasonable period (ie, 4 to 6 months) to check for evidence of LV function. The appearance of persistent hypotension or clinically relevant renal dysfunction should be considered an indication for ACE inhibitor dose reduction or withdrawal (at least temporarily).
Question 4
Do the suggested pathophysiological mechanisms provide a satisfactory explanation of ACE inhibitor clinical effects?
Even if randomized clinical trials alone cannot provide answers on specific pathophysiological mechanisms, the results of ACE inhibitor trials in patients with LV dysfunction do appear to fit the remodeling hypothesis based on experimental studies and represent a good example of the consistency of a mechanistic hypothesis with the clinical data. The exploratory analysis of echo data from GISSI-3 supports this hypothesis in a large, relatively unselected population of patients treated very early after AMI. Although the changes observed in LV volumes are small, they are statistically and clinically significant, as already shown in a subgroup of patients from the SAVE trial. A small decrease in LV volume in the whole population is consistent with a reduction in the incidence of LV dysfunction.
Post hoc analyses of randomized clinical trials suggest that additional mechanisms (vasodilator and neurohormonal effects), in addition to the effect on long-term remodeling, might contribute substantially to the favorable effect of ACE inhibitors. This is suggested by the early beneficial effects (days 0 through 7, Fig 2⇑) documented in GISSI-3 and ISIS-4 and the reduced number of ischemic events reported by the SOLVD and SAVE trials after long-term ACE inhibition (although as expected no evidence of such an effect has been found with the short-term treatments in GISSI-3 and ISIS-4).
In particular, activation of the renin-angiotensin system in the first few days after AMI may increase heart rate and systemic vascular resistance and decrease coronary artery perfusion, which may lead to infarct expansion. The early benefit observed in GISSI-3, ISIS-4, and CSI-1 could be explained in this way.
Summary Statements
1. Patients with signs or symptoms of LV dysfunction at any time after AMI warrant prompt initiation of long-term (lifelong?) ACE inhibitor treatment unless contraindications exist.
2. Treatment of AMI patients with ACE inhibitors may be started the first day after timely and careful observation of their hemodynamic and clinical status and after administration of routinely recommended treatments (thrombolysis, aspirin, and β-blockers). No absolute "efficacy" criteria currently are available to recommend selection of preferential subgroups in the early phase of AMI. 3. Within the time frame of 24 hours after AMI, there is no evidence that in relatively unselected AMI patients early treatment with ACE inhibitors provides more efficacy. However, because mortality is highest in the acute phase of AMI, treatment should not be delayed unnecessarily.
4. Discontinuing ACE inhibitor treatment that was begun in the early phase of AMI should be considered in patients without asymptomatic LV dysfunction after 4 to 6 weeks. Further reassessment of LV function might be considered 4 to 6 months after AMI.
5. The dose of an ACE inhibitor can be individualized on the basis of safety criteria (eg, hemodynamic response) because simple criteria of efficacy, especially in the early phase, are not available. However, the target dose should be that used in the clinical trials.
6. A planned meta-analysis of existing trials should allow more reliable focusing on predefined subgroups of patients at higher risk of side effects or with better-defined profiles of potential benefit. 
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